Department of Hepatic Surgery, Third Affiliated Hospital of Naval Medical University, Shanghai, China; Eastern Hepatobiliary Clinical Research Institute, Third Affiliated Hospital of Navy Military Medical University, Shanghai, China.
Department of General Surgery, Cancer Center, Division of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China; School of Clinical Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
Int J Surg. 2022 Sep;105:106843. doi: 10.1016/j.ijsu.2022.106843. Epub 2022 Aug 19.
Alpha-fetoprotein (AFP) and prothrombin induced by vitamin K absence-II (PIVKA-II) are two commonly used biomarkers for detection and prognostic prediction of hepatocellular carcinoma (HCC). This study sought to evaluate and compare the use of these two biomarkers to detect HCC, as well as predict postoperative early recurrence (within 2 years after HCC resection).
Data on consecutive patients who underwent curative resection for HCC between 2014 and 2020 was prospectively collected and reviewed. Serum AFP and PIVKA-II levels within one week before surgery or at the time of detection of early recurrence were assessed; preoperative AFP positivity (≥20 ng/ml) and preoperative PIVKA-II positivity (≥40 mAU/ml) were examined relative to recurrence using univariate and multivariate Cox-regression analyses.
Among 751 patients who underwent curative HCC resection, 589 (78.4%) patients had preoperative PIVKA-II positivity versus 498 (66.3%) patients had preoperative AFP positivity (P < 0.001). With a median follow-up of 41.6 months, 370 (50.1%) patients had an early HCC recurrence; among patients with an early recurrence, the proportion of patients with PIVKA-II positivity versus AFP positivity (76.5% vs. 60.0%, P = 0.002) was higher. On multivariate analysis, preoperative PIVKA-II positivity, but not preoperative AFP positivity was an independent risk factor to predict early recurrence after HCC resection.
AFP and PIVKA-II are useful biomarkers to detect resectable HCC and predict early recurrence after HCC resection, with the latter showing higher rates of positivity. Preoperative PIVKA-II positivity was independently associated with early recurrence following HCC resection.
甲胎蛋白(AFP)和维生素 K 缺乏诱导的凝血酶原(PIVKA-II)是两种常用于检测和预测肝细胞癌(HCC)的生物标志物。本研究旨在评估和比较这两种生物标志物用于检测 HCC 以及预测 HCC 切除术后早期复发(切除后 2 年内)的能力。
前瞻性收集并回顾了 2014 年至 2020 年间连续接受 HCC 根治性切除术的患者的数据。评估手术前 1 周内或早期复发时的血清 AFP 和 PIVKA-II 水平;使用单变量和多变量 Cox 回归分析,检查术前 AFP 阳性(≥20ng/ml)和术前 PIVKA-II 阳性(≥40mAU/ml)与复发的关系。
在 751 例接受 HCC 根治性切除术的患者中,589 例(78.4%)患者术前 PIVKA-II 阳性,498 例(66.3%)患者术前 AFP 阳性(P<0.001)。中位随访 41.6 个月后,370 例(50.1%)患者发生 HCC 早期复发;在早期复发患者中,PIVKA-II 阳性患者的比例高于 AFP 阳性患者(76.5% vs. 60.0%,P=0.002)。多变量分析显示,术前 PIVKA-II 阳性而不是术前 AFP 阳性是预测 HCC 切除术后早期复发的独立危险因素。
AFP 和 PIVKA-II 是用于检测可切除 HCC 和预测 HCC 切除术后早期复发的有用生物标志物,后者的阳性率更高。术前 PIVKA-II 阳性与 HCC 切除术后早期复发独立相关。